Search the Newsreel

HC Wainwright Has Pessimistic View of Savara FY2029 Earnings

HC Wainwright has revised its FY2029 EPS forecast for Savara Inc. (NASDAQ:SVRA) down to $0.09 from $0.11, while projecting FY2030 EPS at $0.37. This revision is still notably above the current full-year consensus estimate of a $0.57 loss per share. Savara recently reported a …

How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf

Savara Inc. reported a wider Q2 2026 net loss of US$40.23 million and filed a US$108.30 million shelf registration for common shares, primarily for an ESOP-related offering. Despite the financial losses and potential dilution, the company's investment narrative remains tied to upcoming regulatory decisions …

SAVARA Q2 EPS USD -0.16

The article reports that Savara (SVRA) announced its Q2 Earnings Per Share (EPS) as USD -0.16. This financial figure indicates the company's profitability during the second quarter.

Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Savara (NASDAQ:SVRA) announced its quarterly earnings, reporting a loss of $0.16 per share, which missed the consensus estimate by $0.02. Shares fell by $0.16 to $5.57 during Tuesday trading. The company maintains a "Moderate Buy" consensus rating from analysts, with an average target price …

Savara (SVRA) Earnings Date and Reports 2026

Savara Extends MOLBREEVI Patent Protection to 2041

Savara Inc. has secured patent protection in Europe and Australia for its investigational lung-disease therapy, MOLBREEVI, extending coverage to March 2041. These patents cover the liquid formulation and add to existing protection for the drug-device combination, strengthening the company's intellectual property portfolio in markets …

Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC significantly increased its stake in Savara Inc. (NASDAQ:SVRA) during the first quarter, purchasing an additional 320,572 shares to own a total of 652,672 shares valued at approximately $3.56 million. Other institutional investors also modified their holdings, with hedge funds and institutions …

Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Savara Inc (SVRA), detailing its current earnings forecast score, analyst ratings, and price targets. Eight analysts have given Savara Inc an average price target of $10.25, with a majority recommending a "Buy." The report also includes recent …

Savara (SVRA) to Announce Quarterly Earnings on Wednesday

Savara (NASDAQ:SVRA) is scheduled to announce its Q2 2026 earnings before market open on Wednesday, August 12th. Analysts predict a loss of $0.14 per share on revenue of $2.00 million, with the earnings call set for August 11th at 4:00 PM ET. The company's …

Savara investors brace for earnings ahead of crucial FDA review By Investing.com

Savara Inc. is set to report second-quarter earnings, with analysts expecting a loss of $0.145 per share. The clinical-stage biotech company is preparing for a crucial FDA decision on its lead drug candidate, molgramostim, for which it has a PDUFA date set for November …

Savara: High-Potential Binary Bet Cruising To PDUFA After A 3 Month Speed Bump (SVRA)

This article revisits Savara Inc. (SVRA), focusing on its APAP BLA filing progress and identifying the upcoming APAP BLA PDUFA as a pivotal near-term catalyst. The author, who previously rated Savara as a "Buy," highlights the company's clinical and regulatory milestones as key investment …

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Savara Inc., a clinical-stage biopharmaceutical company specializing in rare respiratory diseases, announced its participation in the 2026 Jefferies Global Healthcare Conference. Members of their management team will host one-on-one meetings and a fireside chat on June 3rd, 2026. A live webcast and replay of …

Seven Fleet Capital Management LP Grows Stock Holdings in Savara Inc. $SVRA

Seven Fleet Capital Management LP significantly increased its stake in Savara Inc. (NASDAQ:SVRA) by 371.1% in the first quarter, now owning 295,688 shares valued at $1.61 million. This move is part of a broader trend of institutional investment, with such entities collectively holding 87.93% …

Levi & Korsinsky Urges Savara Inc. (SVRA) Shareholders to Act Before Lead Plaintiff Deadline November 7, 2025

Levi & Korsinsky is urging shareholders of Savara Inc. (SVRA) who suffered losses between March 4, 2024, and May 23, 2025, to act before the lead plaintiff deadline of November 7, 2025. A class action lawsuit alleges that Savara Inc. made false and misleading …

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

Savara Inc. announced that the European and Australian Patent Offices have granted patents for the liquid formulation of MOLBREEVI, providing intellectual property protection until March 2041 in both regions. These patents strengthen Savara's position in ex-US markets for its investigational drug, which is in …

SVRA|Savara Inc|Price:5.435|Chg%:-0.075

This article provides a comprehensive stock analysis of Savara Inc (SVRA) from TradingKey, highlighting its relatively weak fundamentals but high growth potential and fairly valued status within the Biotechnology & Medical Research industry. Key insights include very high institutional ownership, recent "Buy" ratings from …

Savara Inc (SVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Savara Inc (SVRA), focusing on its support and resistance levels, various technical indicators, and moving averages. As of July 28, 2026, the stock's price momentum score is 3.86, and it is trading between a resistance level of …

Savara Inc (SVRA) Financial Health: Profitability & Balance Sheet Analysis

Savara Inc (SVRA) currently holds a financial score of 5.22, placing it low within the Biotechnology & Medical Research industry (373 out of 386). The analysis indicates weak financial status and low operating efficiency for the company. Key financial components such as cash and …

Savara Inc (SVRA) Institutional Confidence

Savara Inc (SVRA) has an institutional shareholding score of 10.00, placing it first among 386 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 16.97% quarter-over-quarter to 104.36%. Key institutional shareholders include New Enterprise Associates (NEA), Bain Capital Life …

Savara Inc (SVRA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Savara Inc (SVRA), listing major shareholders and their proportional holdings. It also breaks down shareholding by type, such as investment advisors and hedge funds, and provides a historical view of institutional shareholdings and recent shareholder activity. Additionally, …

Orbimed Advisors LLC Acquires Shares of 635,000 Savara Inc. $SVRA

Savara Inc (SVRA) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides information on Savara Inc (SVRA)'s dividend history and stock splits. It states that Savara Inc has not distributed any dividends over the past 5 years. While it offers a table for dividend dates, no data is currently available.

Savara Inc. (SVRA) Q1 2026 Earnings: Net Loss Widens on Higher R&D Spend, Stock Dips - Short-Term Outlook

Savara, Inc. Revenue Breakdown – NASDAQ:SVRA

This article provides a financial overview of Savara, Inc. (NASDAQ: SVRA) by detailing its revenue breakdown. It lists various financial data points like statements, statistics, dividends, earnings, and segments. The content also mentions the sources of market and reference data used.

Savara Inc (SVRA) Cash Flow

This article provides a detailed cash flow statement for Savara Inc (SVRA), offering both quarterly and annual data for operating, investing, and financing activities. It breaks down various components such as net income from continuing operations, capital expenditures, and net cash flow from common …

Savara Inc. $SVRA Stock Position Boosted by Spruce Street Capital LP

Form 4 Savara Inc For: 24 July By Investing.com

This article reports on a Form 4 filing for Savara Inc. dated July 24. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders …

Savara Inc. CFO Robert Lutz Secures 70,000 Stock Options and 35,000 RSUs in Insider Transaction

Savara Inc.'s Chief Financial and Operating Officer, Robert Lutz, recently acquired 70,000 stock options and 35,000 restricted stock units. This insider transaction signals the leadership's confidence in the company's future performance. The acquisition details are provided for investors monitoring insider activities.

Savara Inc (NASDAQ: SVRA) grants CFO 70,000 options, 35,000 RSUs

Savara Inc. (NASDAQ: SVRA) announced that its Chief Financial & Operating Officer, Robert Matthew Lutz, received equity awards on July 15, 2026. These awards include 35,000 restricted stock units (RSUs) vesting fully on July 15, 2028, and options for 70,000 shares with an exercise …

Savara Inc (SVRA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Savara Inc (SVRA), noting its current valuation score of 7.70, ranking 208 out of 386 in its industry. It highlights the company's P/E ratio of -9.87 and mentions that relevant data for P/B and P/CF ratios have …

Savara stock gains as Phase 3 data support FDA review of inhaled lung therapy

Savara Inc. stock is gaining traction as the company's inhaled lung therapy for pulmonary alveolar proteinosis approaches FDA review, backed by positive Phase 3 clinical trial data. While the company currently has limited commercial revenue, the potential approval of this lead product could significantly …

If You Invested $1,000 in Savara Inc (SVRA)

This article analyzes the historical performance of investing $1,000 in Savara Inc (SVRA) over different timeframes, showing significant returns for 1 and 5-year periods but a loss since its trading inception in 2017. It also provides detailed information about Savara Inc, a biopharmaceutical company …

Here's Why You Should Add Savara Stock to Your Portfolio Now

Savara (SVRA) is highlighted as a strong buy due to the progress of its lead candidate, Molbreevi, for autoimmune pulmonary alveolar proteinosis (aPAP). The company has strong clinical data, is on track with regulatory milestones in the US, Europe, and the UK, and has …